Literature DB >> 1312542

Ras mutations in human pituitary tumors.

H J Karga1, J M Alexander, E T Hedley-Whyte, A Klibanski, J L Jameson.   

Abstract

The cellular basis for pituitary neoplasia is poorly understood. Mutations that activate the ras protooncogenes have been identified in a number of different types of human cancers and potentially represent one of the genetic alterations that occur in pituitary tumors. In this study we examined 19 pituitary tumors for the occurrence of ras mutations. The tumor types included 11 nonfunctioning adenomas, 6 somatotroph adenomas, and 2 prolactinomas. Each of the three ras genes (K-ras, N-ras, and H-ras) was amplified from pituitary tumor DNA using the polymerase chain reaction. Oligonucleotide-specific hybridization was used to screen for mutations that inhibit GTPase activity and cause activation of the ras oncogene. No ras mutations were observed in 18 of the pituitary adenomas. However, a mutation was identified in codon 12 of the H-ras gene (Gly to Val) in a recurrent prolactinoma that was highly invasive and ultimately proved to be fatal. We conclude that ras mutations are uncommon in pituitary adenomas, but may provide a marker for highly invasive tumors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1312542     DOI: 10.1210/jcem.74.4.1312542

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  48 in total

Review 1.  Malignant pituitary tumours.

Authors:  G A Kaltsas; A B Grossman
Journal:  Pituitary       Date:  1998-04       Impact factor: 4.107

2.  Multiple intracranial recurrent tumors with hyperprolactinemia combined with a parasellar malignant fibrous histiocytoma long after transfrontal surgery and irradiation to a pituitary adenoma.

Authors:  M Fujikawa; K Okamura; K Sato; M Shiratsuchi; T Yao; T Mizokami; M Fujishima
Journal:  J Endocrinol Invest       Date:  2001-06       Impact factor: 4.256

Review 3.  Pathogenesis of prolactinomas.

Authors:  Anna Spada; Giovanna Mantovani; Andrea Lania
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 4.  Growth factors in the pathogenesis of prolactin-secreting tumors.

Authors:  C Missale; P F Spano
Journal:  J Endocrinol Invest       Date:  1998-06       Impact factor: 4.256

Review 5.  Familial isolated pituitary adenomas: from genetics to therapy.

Authors:  Federica Guaraldi; Roberto Salvatori
Journal:  Clin Transl Sci       Date:  2011-02       Impact factor: 4.689

Review 6.  Isolation and characterization of novel pituitary tumor related genes: a cDNA representational difference approach.

Authors:  Xun Zhang; Yunli Zhou; Anne Klibanski
Journal:  Mol Cell Endocrinol       Date:  2010-03-06       Impact factor: 4.102

7.  Suberoylanilide hydroxamic acid (SAHA) induces growth arrest and apoptosis in pituitary adenoma cells.

Authors:  S R Sangeetha; Nagendra Singh; John R Vender; Krishnan M Dhandapani
Journal:  Endocrine       Date:  2009-03-17       Impact factor: 3.633

8.  Genomic instability in pituitary adenomas.

Authors:  Janusz Szymas; Karsten Schluens; Wlodzimierz Liebert; Iver Petersen
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

9.  Signaling pathway networks mined from human pituitary adenoma proteomics data.

Authors:  Xianquan Zhan; Dominic M Desiderio
Journal:  BMC Med Genomics       Date:  2010-04-28       Impact factor: 3.063

Review 10.  Acromegaly pathogenesis and treatment.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2009-11-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.